

Pharmatrophix



May 2022

This letter acknowledges the participation of Vestra Clinics in the Phase 2a randomized controlled trial of LM11A-31-BHS in mild to moderate Alzheimer's disease subjects sponsored by Pharmatrophix in partnership with NeuroScios. Dr. Ladislav Pazdera served as the site Principle Investigator.

Subjects for the overall trial were enrolled at 18 sites located in five countries in the EU. Dr. Pazdera and his team were one of the two highest enrolling sites and randomized the first two subjects in the trial. The team successfully screened 39 subjects and 26 were randomized. Communications were timely and efficient; timelines were met and audits found no critical or major findings.

It was a pleasure to collaborate with Dr. Pazdera and his team.



Frank M. Longo

Pharmatrophix, Menlo Park CA, USA



Nikola Helmberg

NeuroScios, Graz, Austria